Prostate cancer most often develops from prostatic intraepithelial neoplasia (PIN) in the prostate gland and can be described as localised, locally advanced or advanced (metastatic). Symptoms may include genito-urinary symptoms such as poor urinary stream and erectile dysfunction, or bone pain in cases where the disease has spread to the bones.
Featured Learning Zones
Prostate cancer is considered a slow growing cancer and is driven by the androgen axis. Subsequently, treatment for hormone sensitive prostate cancer (HSPC) revolves around androgen deprivation therapy (ADT) alongside radiation therapy and chemotherapy.
Related news and insights
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the randomized, double-blind, placebo-controlled Phase III ACIS study of Erleada (apalutamide) and Zytiga (abiraterone acetate) plus prednisone, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT).
Recordati announces the closing of a License and Supply Agreement with Tolmar International Ltd, to commercialise Eligard (leuprorelin acetate), in Europe, Turkey, Russia and other countries.
Bayer announced that the FDA approved a supplemental New Drug Application (sNDA) to add overall survival (OS) and other secondary endpoint data from the Phase III ARAMIS trial to the Nubeqa (darolutamide) Prescribing Information.